Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Aug 12, 2021 4:56pm
207 Views
Post# 33698146

RE:RE:RE:Timelines...

RE:RE:RE:Timelines...The ALT happened in 3 people. Cool your jets.

Its ok you're a bad investor and there is no shame in that. And I get that you're butthurt. Learn from it instead of spreading misinformation. 

Here is a list of my faviorute FUD coming out your a$$: 

1- What is your confidence level that 75mg will be statistically signifigant to placebo over a two week period? 
if you had watched the Wallace video you would clearly see that 75mg provided COX suppression similar to naproxen at 250mg BID

2-
The issue is that they don't know how effective it is at 75mg from a WOMAC (pain relief) score perspective and if it is not as effective as Naproxen who with Arthritis is going to take it if there is no pain releif. 

another variation of the same FUD

3-I don't want to rain on the 352 parade but it's not even in Phase 1 and patents on IP expire in 2032 in the U.S.  Plus 346 is/was the one with hige TAM and blockbuster potential. 

This has been addreessed several times when ATE takes about expanding the pipeline, its literally to extended IP protection for 352 and 340, in addition to another drug for IBD.

4-
Furthermore, have you ever heard of the term "placebo-effect" for drug trials and that being one of the main reasons drug trials fail Phase 2.  So here we are re-doing Phase 2 all over again....if that isn't additional risk then I don't know what is.  

Yet another variation on your BS on 75mg issue you made up. Look up the PK values and cox suppression for 75mg of 346. Indeed you dont know what additional risk is. 
<< Previous
Bullboard Posts
Next >>